Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MGD024 · 1 trial · 8 indications
Observation of side effects determines the highest safe dose for further study
Observation of side effects determines the highest safe dose for further study
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Escalating doses of MGD024 will be assigned based on safety and tolerability of the previous dose level. |
| Name | Type | Description |
|---|---|---|
| MGD024 | DRUG | MGD024 is a CD123 x CD3 bispecific DART® molecule designed to target CD123-expressing leukemic cells for elimination by CD3-expressing T lymphocytes. |
Inclusion Criteria: * Adult patients at least 18 years of age, able to provide informed consent and willing to comply with all study procedures. * Participants with * primary or secondary acute myeloid leukemia (AML) except acute promyelocytic leukemia, * primary or secondary myelodysplastic s...
MGD024 is an investigational therapy being studied for the treatment of relapsed or refractory hematologic malignancies, including acute myeloid leukemia. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being evaluated in a clinical trial enrolling patients with various blood cancers.
MGD024 targets CD123, a protein expressed on the surface of certain cells. CD123 is a target of interest in hematologic malignancies because it is found on leukemic cells and other abnormal cells. By targeting CD123, MGD024 aims to direct the immune system against these malignant cells.
MGD024 is being developed by MacroGenics, Inc., a biopharmaceutical company. MacroGenics is publicly traded on the Nasdaq under the ticker symbol MGNX. The company is conducting clinical trials to evaluate the safety and efficacy of MGD024 in patients with hematologic malignancies.
MGD024 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities for commercial use. The Phase 1 trial is designed to assess the safety, tolerability, and preliminary activity of MGD024 in patients with relapsed or refractory hematologic malignancies.
MGD024 is being studied in a Phase 1 clinical trial with the identifier NCT05362773. This trial is titled 'A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies' and is currently active but not recruiting. The trial is enrolling approximately 130 participants in the United States.